%0 Journal Article
%T Serum procalcitonin levels in prostate cancer: A new biomarker?
%A Alper £¿t¨¹n£¿temur
%A Hasan A Atalay
%A L¨¹tfi Canat
%A Osman Can
%A £¿lter Alkan
%J Urologia Journal
%@ 1724-6075
%D 2018
%R 10.1177/0391560317752600
%X To examine the role of serum procalcitonin as a biomarker for the detection of prostate cancer in patients with a serum prostate-specific antigen less than 20.0£¿ng/mL. The prospective study included patients with a prostate-specific antigen level of 2¨C20£¿ng/mL, who underwent prostate biopsy. Clinical and pathological data such as age, prostate volume, prostate-specific antigen, procalcitonin, and Gleason score were reviewed. All patients were divided into three groups with total prostate-specific antigen level between 2 and 4£¿ng/mL, 4.1 and 10£¿ng/mL, and 10.1 and 20£¿ng/mL. Of 227 patients who underwent biopsy, prostate cancer was diagnosed in 74 (32.6%) patients and the remaining 153 patients had a benign condition. The difference in mean serum procalcitonin values was significantly higher in the prostate cancer compared with the benign group (0.06£¿¡À£¿0.03 vs 0.04£¿¡À£¿0.03£¿ng/mL; p£¿=£¿0.0001). Using a threshold of 0.045£¿ng/mL, procalcitonin was 54.1% sensitive and 80.3% specific (area under curve£¿=£¿0.683). Serum procalcitonin levels were not able to differentiate between prostate cancer patients with prostate-specific antigen level of 2¨C4, 4.1¨C10, and 10.1¨C20£¿ng/mL. Based on this prospective study, procalcitonin can be a novel supplementary biomarker to increase the accuracy of prostate cancer screening
%K Biomarker
%K procalcitonin
%K prostate cancer
%U https://journals.sagepub.com/doi/full/10.1177/0391560317752600